Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

Daniel P. Petrylak, MD
Published: Wednesday, Jul 12, 2017



Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

There are many combinations that are currently being investigated, explains Petrylak. There is a combination of ramucirumab (Cyramza) plus pembrolizumab. Additionally, there is a study trying to determine if using anti-angiogenesis agents reverses the resistance that is seen with immunotherapy.

There are studies that are combining agents such as OX40 agonists, states Petrylak. Other combinations are currently being studied, as well as upfront chemotherapy and immunotherapy.



Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

There are many combinations that are currently being investigated, explains Petrylak. There is a combination of ramucirumab (Cyramza) plus pembrolizumab. Additionally, there is a study trying to determine if using anti-angiogenesis agents reverses the resistance that is seen with immunotherapy.

There are studies that are combining agents such as OX40 agonists, states Petrylak. Other combinations are currently being studied, as well as upfront chemotherapy and immunotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x